会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明公开
    • 인간 혈액응고 7인자 유도체의 대량 생산 방법
    • 大量生产因子VII模拟的方法
    • KR1020150026024A
    • 2015-03-11
    • KR1020130104308
    • 2013-08-30
    • 한미약품 주식회사
    • 강희철김진영이병선김현욱최인영권세창
    • C12N15/85C12N15/12C12P21/02
    • C12N9/6437C07K14/745C12N9/003C12N15/85C12P21/02C12Y105/01003C12Y304/21021
    • The present invention relates to a method of mass-producing human blood coagulation factor VII. More specifically, the present invention relates to a mass-production method of human blood coagulation factor VII derivatives, and a cell line for mass-producing human blood coagulation factor VII derivatives, wherein the mass-production method of human blood coagulation factor VII derivatives comprises a) a step of manufacturing an expression vector including i) a base sequence of a dehydrofolate reductase promoter with at least one CCGCCC removed from a GC-rich region, and a base sequence operationally connected thereto and coding the dehydrofolate reductase (DHFR); and ii) a base sequence of early gene promoters of cytomegalosvirus (CMV), and a base sequence operationally connected thereto and coding the human blood coagulation factor VII derivatives; b) a step of transforming animal cell lines with the expression vector of step a); c) a step of cultivating the transformed animal cell lines at step b) under existence of dehydrofolate reductase inhibitors and selecting cell lines expressing human blood coagulation factor VII derivatives at a high efficiency; and d) a step of adding at least one selected from the group consisting of sodium butylate, vitamin K and a culture medium additive to the selected animal cell lines of step c) and cultivating. The present invention can be usefully applied to manufacture of a hemophilia medicine as the human blood coagulation factor VII derivatives can be expressed at a high efficiency and a large quantity by using a vector with GC-rich repeated sequences deleted at a DHFR promotor site.
    • 本发明涉及一种批量生产人凝血因子VII的方法。 更具体地,本发明涉及人凝血因子VII衍生物的批量生产方法和用于大规模生产人凝血因子VII衍生物的细胞系,其中人凝血因子VII衍生物的批量生产方法包括 a)制备表达载体的步骤,所述步骤包括:i)从富含GC的区域除去至少一个CCGCCC的脱氢叶酸还原酶启动子的碱基序列和与其操作连接并编码脱氢叶酸还原酶(DHFR)的碱基序列; 和ii)巨细胞病毒(CMV)的早期基因启动子的碱基序列和与其可操作地连接并编码人血液凝固因子VII衍生物的碱基序列; b)用步骤a)的表达载体转化动物细胞系的步骤; c)在脱氢叶酸还原酶抑制剂的存在下在步骤b)中培养转化的动物细胞系的步骤,并且以高效率选择表达人凝血因子VII衍生物的细胞系; 和d)向步骤c)的所选择的动物细胞系中添加选自丁酸钠,维生素K和培养基添加剂中的至少一种的步骤,并进行培养。 本发明可有效地应用于制造血友病药物,因为人血液凝固因子VII衍生物可以通过使用在DHFR启动子位点缺失GC富集重复序列的载体以高效率和大量表达。
    • 3. 发明公开
    • 신규한 융합 단백질, 이를 발현하는 세포주 및 이의 제조방법
    • 新型融合蛋白,表达其的细胞系及其制备方法
    • KR1020080042747A
    • 2008-05-15
    • KR1020070114360
    • 2007-11-09
    • 보령제약 주식회사
    • 김상린단현광임상민구재경신주엽김명환임종진정찬희
    • C07K19/00
    • C07K14/505A61K38/1816A61K47/64C07K14/76C07K2319/00C07K2319/31C12N9/003C12N15/85C12N2510/02C12Y105/01003
    • A novel fusion protein of human albumin and human erythropoietin(EPO) is provided to enhance in vivo half life and blood corpuscle production-promoting ability of EPO and minimize influence to characteristics and protein three-dimensional structure of EPO by using a linker having a repetitive amino acid sequence in fusion process. A novel fusion protein is prepared by linking human albumin to human erythropoietin(EPO) by using a linker having the amino acid sequence of (GGSGG)n in which n is an integer from 3 to 5, and has the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6. A gene encoding the fusion protein has the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3 or SEQ ID NO:5. A cell line expressing the fusion protein is produced by transforming a host cell such as CHO(Chinese hamster ovary) cell with an expression vector containing a human albumin gene, a linker having the nucleotide sequence of (GGAGGAAGCGGAGGA)n and a human erythropoietin gene and an expression vector containing a gene encoding dihydrofolate reductase(DHFR). Further, the cell line is a CHO/dhfr- of which a dhfr gene is in deficiency.
    • 提供人白蛋白和人促红细胞生成素(EPO)的新型融合蛋白,以增强EPO的体内半衰期和血小板产生促进能力,并通过使用具有重复性的接头对EPO的特征和蛋白质三维结构的影响最小化 融合过程中的氨基酸序列。 通过使用具有(GGSGG)n的氨基酸序列的接头,其中n为3至5的整数,并且具有SEQ ID NO:1的氨基酸序列,将人白蛋白与人促红细胞生成素(EPO)连接,制备新的融合蛋白 NO:2,SEQ ID NO:4或SEQ ID NO:6。 编码融合蛋白的基因具有SEQ ID NO:1,SEQ ID NO:3或SEQ ID NO:5的核苷酸序列。 通过用含有人白蛋白基因的表达载体,具有(GGAGGAAGCGGAGGA)n的核苷酸序列的接头和人促红细胞生成素基因转化宿主细胞如CHO(中国仓鼠卵巢)细胞,产生表达融合蛋白的细胞系, 含有编码二氢叶酸还原酶(DHFR)的基因的表达载体。 此外,细胞系是CHO / dhfr-其中dhfr基因是缺乏的。
    • 6. 发明授权
    • 바이러스 벡터를 이용하여 단백질의 상호작용을 측정하는 방법
    • 使用病毒载体测定蛋白质 - 蛋白质相互作用的方法
    • KR101029972B1
    • 2011-04-20
    • KR1020100058213
    • 2010-06-18
    • 콜마파마(주)서울대학교산학협력단
    • 허원기송용범이태규신동승정재연최은욱안지선
    • C12Q1/70C12N15/86C12Q1/66C12Q1/02
    • C12N15/86C12Y105/01003C12Y302/01023C12Y304/22044C12Y305/02006G01N33/68
    • PURPOSE: A method for real time analysis of protein interaction in animal cells is provided to directly observe interaction and change between proteins by a microscope. CONSTITUTION: A method for measuring interaction of a protein comprises: a step of providing viral genome DNA by cloning a restriction enzyme recognition base sequence, two positions-specific recombinant enzyme recognition base sequence, and a gene encoding a first fragment of a reporter protein; a step of treating the viral genome DNA with a restriction enzyme to prepare two linear viral genome DNA fragments; a step of providing a transport vector containing DNA encoding a first target protein; a step of transducing the recombinant vector to a host cell to prepare the first recombinant virus; a step of providing a second recombinant virus containing a gene encoding a second fragment; and a step of infecting the first and second recombinant viruses to a target cells and measuring coloration.
    • 目的:提供一种实时分析动物细胞蛋白质相互作用的方法,通过显微镜直接观察蛋白质之间的相互作用和变化。 构成:用于测定蛋白质相互作用的方法包括:通过克隆限制酶识别碱基序列,两个位置特异性重组酶识别碱基序列和编码报道蛋白的第一个片段的基因来提供病毒基因组DNA的步骤; 用限制酶处理病毒基因组DNA以制备两条线性病毒基因组DNA片段的步骤; 提供含有编码第一靶蛋白的DNA的转运载体的步骤; 将重组载体转导至宿主细胞以制备第一重组病毒的步骤; 提供含有编码第二片段的基因的第二重组病毒的步骤; 以及将第一和第二重组病毒感染到靶细胞并测量着色的步骤。
    • 10. 发明公开
    • 인간 난포자극 호르몬을 대량으로 생산하는 방법
    • 人类激素刺激大鼠生产方法
    • KR1020050032709A
    • 2005-04-08
    • KR1020030068641
    • 2003-10-02
    • 주식회사 프로젠
    • 양세환성영철나규흠이성희김원배
    • C12N15/85
    • A61K38/44A61K38/00A61K48/00C07K14/59C12N15/85C12N2840/203C12Y105/01003
    • A method for mass production of human follicle stimulating hormone is provided, thereby improving stability of human follicle stimulating hormone production by using an expression vector and recombinant transformant, so that the mass produced human follicle stimulating hormone can be useful for treatment of sterility. An expression vector comprises a human follicle stimulating hormone gene, a promoter sequence of cytomegalovirus early gene, an adenovirus tripartite leader sequence, a polyadenylation motif sequence and a dihydrofolate reduatase gene, wherein the human follicle stimulating hormone gene comprises human follicle stimulating hormone alpha subunit gene of SEQ ID NO:1, internal ribosomal entry site of SEQ ID NO:7 and human follicle stimulating hormone beta subunit gene of SEQ ID NO:2; the promoter sequence of cytomegalovirus early gene has the nucleotide sequence of SEQ ID NO:8; the adenovirus tripartite leader sequence has the nucleotide sequence of SEQ ID NO:9; the polyadenylation motif sequence is the polyadenylation motif sequence of SV40 virus early gene of SEQ ID NO:11 and/or polyadenylation motif sequence of bovine growth hormone gene of SEQ ID NO:12; and the dihydrofolate reduatase gene has the nucleotide sequence of SEQ ID NO:10. A recombinant transformant(KCLRF-BP-00082) mass producing the human follicle stimulating hormone is produced by transforming a host cell with the expression vector, wherein the recombinant transformant is derived from Chinese Hamster Ovary(CHO). The method for mass production of human follicle stimulating hormone comprises culturing the recombinant transformant.
    • 提供了大量生产人类促卵泡激素的方法,从而通过使用表达载体和重组转化体来提高人类促卵泡激素产生的稳定性,使得大量产生人类促卵泡激素可用于治疗无菌性。 表达载体包括人卵泡刺激素基因,巨细胞病毒早期基因的启动子序列,腺病毒三方前导序列,多腺苷酸化基序序列和二氢叶酸还原酶基因,其中人卵泡刺激素基因包含人卵泡刺激素α亚基基因 SEQ ID NO:1的内部核糖体进入位点和SEQ ID NO:2的人促卵泡激素β亚基基因; 巨细胞病毒早期基因的启动子序列具有SEQ ID NO:8的核苷酸序列; 腺病毒三方前导序列具有SEQ ID NO:9的核苷酸序列; 多腺苷酸化基序序列是SEQ ID NO:11的SV40病毒早期基因和/或SEQ ID NO:12的牛生长激素基因的聚腺苷酸基序列的多腺苷酸基序列; 并且所述二氢叶酸还原酶基因具有SEQ ID NO:10的核苷酸序列。 通过用表达载体转化宿主细胞产生产生人促卵泡激素的重组转化体(KCLRF-BP-00082),其中重组转化体衍生自中国仓鼠卵巢(CHO)。 大量生产人卵泡刺激素的方法包括培养重组转化体。